Patients with advanced retinitis pigmentosa who received intravitreal optogenetics gene therapy in a phase 1/2a study experienced improved visual acuity from baseline at 16 weeks, according to a speaker.
“Nanoscope’s polychromatic opsin is activated in ambient light, generates significant photocurrent and requires no goggles,” Santosh Kumar Mahapatra, MS, said at Retina Subspecialty Day at the virtual American Academy of Ophthalmology meeting.
The single intravitreal injection of vMCO-010 (Nanoscope) targets bipolar cells instead of retinal ganglion cells. Optogenetics gene
Uncategorized